Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against ICON PLC
On February 12, 2025, in the United States District Court for the Southern District of New York, Bronstein, Gewirtz & Grossman, LLC, a leading national securities law firm, announced the filing of a class action lawsuit against ICON PLC (“ICON” or “the Company”) (NASDAQ: ICLR) and certain of its officers. The complaint alleges that the Company and its officers violated the federal securities laws by making materially false and misleading statements and omitting key information regarding the Company’s business, operations, and financial condition.
Class Definition
This lawsuit seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired ICON securities between July 27, 2023, and October 23, 2024, both dates inclusive (the “Class Period”). The complaint alleges that defendants made false and misleading statements and/or failed to disclose that:
- ICON was experiencing significant operational challenges, including delays in the execution of certain contracts and the loss of key clients.
- The Company’s financial results were negatively impacted by these operational challenges.
- Defendants lacked a reasonable basis for their positive statements about the Company’s business prospects.
Impact on Individual Investors
If you purchased or otherwise acquired ICON securities during the Class Period, you may be entitled to recover your losses, including damages. The complaint is seeking to recover damages on behalf of the Class. To be eligible for damages, you must have purchased or otherwise acquired ICON securities during the Class Period. If you wish to learn more about this action and your rights as a shareholder, please contact Bronstein, Gewirtz & Grossman, LLC, by emailing [email protected] or calling 212-697-6484. You can also join this class action by visiting
Impact on the World
The filing of this class action lawsuit against ICON PLC may have significant implications for the biopharmaceutical industry as a whole. The allegations made in the complaint, if proven true, could potentially damage the reputation of ICON and the biopharmaceutical industry as a whole. Furthermore, this lawsuit could lead to increased scrutiny of other companies in the industry, potentially leading to increased regulation and oversight. It is important for investors to stay informed about developments in this case and the biopharmaceutical industry as a whole.
Conclusion
Bronstein, Gewirtz & Grossman, LLC’s filing of a class action lawsuit against ICON PLC and certain of its officers alleges that the Company and its officers violated federal securities laws by making false and misleading statements and omitting key information regarding the Company’s business, operations, and financial condition during the Class Period. If you purchased or otherwise acquired ICON securities during the Class Period, you may be entitled to recover your losses. To learn more about this action and your rights as a shareholder, please contact Bronstein, Gewirtz & Grossman, LLC. This lawsuit could have significant implications for the biopharmaceutical industry as a whole, potentially leading to increased scrutiny and regulation.
It is important for investors to stay informed about developments in this case and the biopharmaceutical industry. We will continue to monitor this situation closely and provide updates as new information becomes available.
